Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | LCK | P06239 | 12/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6058064 | 0.92 | LCK (0.71) | ALDH1A1LCKTP53HPGDHSD17B10 | |
| SCHEMBL6058160 | 0.85 | LCK (0.82) | NPC1RAB9AALDH1A1LMNALCK | |
| SCHEMBL21772286 | 0.80 | LCK (0.64) | LCKHSD17B10FYNSRC | |
| SCHEMBL6057883 | 0.80 | LCK (1.00) | NPC1RAB9AALDH1A1LMNALCK | |
| Dimethylamine SCHEMBL6058137 | 0.78 | LCK (0.74) | NPC1RAB9AALDH1A1LMNALCK | |
| SCHEMBL6058264 | 0.78 | LCK (0.89) | LCKFYNSRC | |
| SCHEMBL21681983 | 0.78 | LCK (0.62) | LCKFYNSRC | |
| SCHEMBL11592582 | 0.77 | LMNA (0.56) | NPC1RAB9AALDH1A1LMNALCK | |
| SCHEMBL6058279 | 0.77 | LCK (0.81) | LCKFYNSRC | |
| SCHEMBL21709937 | 0.77 | NPC1 (0.70) | NPC1RAB9AALDH1A1LMNALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071316-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | Kineta Immuno-Oncology LLC | 2020-03-05 | — | — | US | disclosed |
| US-20200071316-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | Kineta Immuno-Oncology LLC | 2020-03-05 | — | — | US | disclosed |
| WO-2020033782-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-1\" PATHWAY AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071316-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | RARB, RARG, RARA | NPC1 3269/4885RAB9A 1570/4885ALDH1A1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.